Emergent BioSolutions Inc. (EBS)

49.99
NYSE : Health Technology
Prev Close 50.61
Day Low/High 49.89 / 50.65
52 Wk Low/High 30.55 / 55.91
Avg Volume 350.60K
Exchange NYSE
Shares Outstanding 49.82M
Market Cap 2.52B
EPS 2.00
P/E Ratio 36.67
Div & Yield N.A. (N.A)

Latest News

Emergent BioSolutions Reaches Analyst Target Price

Emergent BioSolutions Reaches Analyst Target Price

In recent trading, shares of Emergent BioSolutions Inc have crossed above the average analyst 12-month target price of $45.75, changing hands for $46.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

First Week of February 16th Options Trading For Emergent BioSolutions (EBS)

First Week of February 16th Options Trading For Emergent BioSolutions (EBS)

Investors in Emergent BioSolutions Inc saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EBS options chain for the new February 16th contracts and identified one put and one call contract of particular interest.

EBS Crosses Above Average Analyst Target

EBS Crosses Above Average Analyst Target

In recent trading, shares of Emergent BioSolutions Inc have crossed above the average analyst 12-month target price of $44.25, changing hands for $45.48/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Emergent BioSolutions Awarded Department Of National Defence Contract To Supply Anthrasil To The Canadian Government

Emergent BioSolutions Awarded Department Of National Defence Contract To Supply Anthrasil To The Canadian Government

Health Canada approves Anthrasil® under Extraordinary Use New Drug Regulations

Six Off the Beaten Path Healthcare Stock Gems

Six Off the Beaten Path Healthcare Stock Gems

These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.

Emergent BioSolutions Announces Closing Of New $200 Million Senior Secured Credit Facility

Emergent BioSolutions Announces Closing Of New $200 Million Senior Secured Credit Facility

Facility Includes an Accordion Feature Enabling $100 Million of Additional Capacity for a Total of $300 Million

Biotech movers: Ionis Drops After GSK Bows Out of Partnership

Biotech movers: Ionis Drops After GSK Bows Out of Partnership

Ionis retained all rights to inotersen and IONIS-FB-LRx as part of reprioritizing its pipeline and a strategic review of its Rare Diseases business.

TheStreet Quant Rating: B (Buy)